A recent study indicates that individuals who discontinue popular GLP-1 drugs like Mounjaro or Wegovy may regain reduced body mass at a significantly accelerated pace than those who stop conventional diet and exercise plans.
Findings released in a major medical journal points out that while obese people frequently drop substantial amounts of their body weight while undergoing treatment, the weight comes back at an average rate of 0.8 kg per month after stopping.
"People buying these drugs should be cognizant of the risk of rapid weight regain when the medication is stopped," warns researcher Dr. Susan Jebb.
Such speed of recovery suggests a return to starting mass within about one and a half years.
Weighing Therapies
The analysis, which examined dozens of trials involving thousands of patients, contrasted the effects of GLP-1 agonists with other pills.
The team emphasize that individuals who lose weight through dieting generally have a less rapid weight regain—perhaps 100 grams monthly—after stopping.
Understanding the Rapid Rebound
Experts propose the way of the drugs explains the amplified regain.
GLP-1 drugs mimic a natural hormone called glucagon-like peptide-1, which helps regulate feelings of fullness.
"Sustained high doses of the hormone concentrations several times higher than the body's typical production might result in the system to produce less of its own natural hormone, and could reduce sensitivity to its effects," explained Dr. Adam Collins, a nutrition specialist.
"Stopping of this hormone supplement results in hunger is unsuppressed, making overeating a significant risk."
An Ongoing Issue?
Medical guidelines suggest the jabs for people with obesity-related medical conditions, alongside prescribed lifestyle changes.
A number of clinicians say that, given the likelihood of weight regain, the therapy should be considered life-long.
This perspective is supported by pharmaceutical companies, who say that the findings "underscore the chronic character of excess weight," akin to managing diseases like high blood pressure.
User Testimonies
Individuals who have come off the medication describe a sudden return of cravings.
"I experienced a switch flipping and you're instantly starving," described a patient.
This challenge is worsened if patients have not adopted permanent lifestyle or habit modifications during treatment.
Significant Adoption
Recent estimates show that a significant number of adults in the UK have tried weight-loss jabs in the last 12 months, with interest remaining high.
- Use is more common among females compared to males.
- The middle-aged age group shows the greatest level of interest.
- Many obtain the drugs through private healthcare rather than public health services.
Finally, experts stress that while GLP-1 drugs are potent agents for shedding pounds, they are not a permanent cure and maintained weight loss relies on integrated lifestyle support.
